Effect of glucocorticoid withdrawal on glucocorticoid inducing bone impairment
- PMID: 27402272
- DOI: 10.1016/j.bbrc.2016.07.036
Effect of glucocorticoid withdrawal on glucocorticoid inducing bone impairment
Abstract
Glucocorticoid (GC) withdrawal after a short-term use was common in clinical practice like immediate post-transplant period. However, previous studies without setting age-control group failed to determine whether the BMD recovery was sufficient and whether it is necessary to accept anti-osteoporosis therapy after GC withdrawal. The aim of this study was to investigate the effect of GC withdrawal on bone impairment in glucocorticoid-induced osteoporosis (GIOP) rats. Twenty-four female Sprague-Dawley rats (3 months' old) were randomly divided into two treatment groups: an untreated age-control group (Con, n = 12); another group receiving a dexamethasone injection (DEXA, n = 12). Animals in the Con group were euthanized at 3rd month (M3) and 6th month (M6), respectively. Six rats in the DEXA group were euthanized at 3rd month (M3), whereas GC intervention was withdrew in the remaining animals of DEXA group, which were euthanized at the end of 6th month (M6). Bone mass, bone microarchitecture, biomechanical properties of vertebrae, morphology, serum levels of PINP and β-CTX were evaluated. Compared with the Con(M3) group, the Con(M6) group showed significantly better bone quantity, morphology and quality. Compared with the Con(M3) group, the DEXA (M3) group showed significantly lower BMC, BMD, BS/TV, BV/TV, Tb.N, Tb.Th, vBMD, bone strength, compressive displacement, energy absorption capacity, PINP levels, β-CTX levels, and damaged trabecular morphology. And the same change trend was observed in the comparison between the Con(M6) group and DEXA (M6) group. Compared with the DEXA (M3) group, the DEXA (M6) group showed significantly higher BMC, BMD and AREA, but no significant difference in BS/TV, BV/TV, SMI, Tb.N, Tb.Th, Tb.Sp, vBMD, bone strength, bone stiffness, compressive displacement, energy absorption capacity, PINP levels, β-CTX levels, and improvement in trabecular morphology was observed. These results indicate that the reverse effect of GC withdrawal for 3 months on bone impairment in GIOP rats was insufficient, which implied that related anti-osteoporosis treatment might be still necessitated after GC withdrawal in clinical setting.
Keywords: Bone impairment; GC withdrawal; GIOP.
Copyright © 2016 Elsevier Inc. All rights reserved.
Similar articles
-
Effects of combined ovariectomy with dexamethasone on rat lumbar vertebrae.Menopause. 2016 Apr;23(4):441-50. doi: 10.1097/GME.0000000000000547. Menopause. 2016. PMID: 26694734
-
Variance of spinal osteoporosis induced by dexamethasone and methylprednisolone and its associated mechanism.Steroids. 2015 Oct;102:65-75. doi: 10.1016/j.steroids.2015.07.006. Epub 2015 Jul 26. Steroids. 2015. PMID: 26216207
-
[PHASIC CHANGES OF BONE MASS, BONE TURNOVER MARKERS, AND ESTROGEN LEVELS AT DIFFERENT TIME POINTS AFTER GLUCOCORTICOID INTERVENTION AND THEIR CORRELATION IN RATS].Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2015 Mar;29(3):307-14. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2015. PMID: 26455196 Chinese.
-
A novel flavonoid C-glucoside from Ulmus wallichiana preserves bone mineral density, microarchitecture and biomechanical properties in the presence of glucocorticoid by promoting osteoblast survival: a comparative study with human parathyroid hormone.Phytomedicine. 2013 Nov 15;20(14):1256-66. doi: 10.1016/j.phymed.2013.07.007. Epub 2013 Aug 6. Phytomedicine. 2013. PMID: 23928508
-
[Dynamic effects of glucocorticoid on bone mineral density and microarchitecture: experiment with rats].Zhonghua Yi Xue Za Zhi. 2008 Aug 19;88(32):2281-4. Zhonghua Yi Xue Za Zhi. 2008. PMID: 19087680 Chinese.
Cited by
-
Combined application of mesenchymal stem cells and different glucocorticoid dosing alleviates osteoporosis in SLE murine models.Immun Inflamm Dis. 2024 Jun;12(6):e1319. doi: 10.1002/iid3.1319. Immun Inflamm Dis. 2024. PMID: 38888448 Free PMC article.
-
The osteocytic actions of glucocorticoids on bone mass, mechanical properties, or perilacunar remodeling outcomes are not rescued by PTH(1-34).Front Endocrinol (Lausanne). 2024 Jul 18;15:1342938. doi: 10.3389/fendo.2024.1342938. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39092287 Free PMC article.
-
Effects of the Phosphodiesterase-5 (PDE-5) Inhibitors, Avanafil and Zaprinast, on Bone Remodeling and Oxidative Damage in a Rat Model of Glucocorticoid-Induced Osteoporosis.Med Sci Monit Basic Res. 2018 Mar 13;24:47-58. doi: 10.12659/MSMBR.908504. Med Sci Monit Basic Res. 2018. PMID: 29557941 Free PMC article.
-
Differences in bone turnover markers and injury risks between local and international horses: A Victorian Spring Racing Carnival study.Equine Vet J. 2025 Mar;57(2):333-346. doi: 10.1111/evj.14098. Epub 2024 Apr 18. Equine Vet J. 2025. PMID: 38634210 Free PMC article.
-
Promotion effect of extracts from plastrum testudinis on alendronate against glucocorticoid-induced osteoporosis in rat spine.Sci Rep. 2017 Sep 6;7(1):10617. doi: 10.1038/s41598-017-10614-5. Sci Rep. 2017. PMID: 28878388 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous